Patents by Inventor Edward Skolnik

Edward Skolnik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240016951
    Abstract: The present disclosure provides compositions and methods for treating allograft vasculopathy, for treating Moyamoya Diseases (MMD) and Moyamoya Syndrome (MMS), for treating inhibiting or preventing unwanted intimal proliferation in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
    Type: Application
    Filed: December 30, 2022
    Publication date: January 18, 2024
    Inventors: Damon Banks, Catherine A. Nester, Edward Skolnik, Markus Walz, Frank Rutsch, Yvonne Nitschke
  • Patent number: 9457016
    Abstract: Methods for treating autosomal dominant polycystic kidney disease (ADPKD) are described herein. More particularly, methods described herein relate generally to administering glutaminase1 inhibitors to subjects afflicted with ADPKD. Accordingly, the use and application of compounds or agents that inhibit glutaminase1 for treating ADPKD or for use in a medicament for treating ADPKD are encompassed herein.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: October 4, 2016
    Assignee: New York University
    Inventors: Edward Skolnik, Zhai Li
  • Publication number: 20150204846
    Abstract: Methods for screening to identify agents capable of modulating PI3KC2?/mast cell activation are also encompassed herein as are methods of using such agents to treat IgE-mediated allergic disorders.
    Type: Application
    Filed: May 15, 2013
    Publication date: July 23, 2015
    Inventors: Edward Skolnik, Zhai Li, Shekhar Srivastava
  • Publication number: 20150065486
    Abstract: Methods for treating autosomal dominant polycystic kidney disease (ADPKD) are described herein. More particularly, methods described herein relate generally to administering glutaminase1 inhibitors to subjects afflicted with ADPKD. Accordingly, the use and application of compounds or agents that inhibit glutaminase1 for treating ADPKD or for use in a medicament for treating ADPKD are encompassed herein.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Edward Skolnik, Zhai Li